BioLineRx Ltd (BLRX)

[midastouch017]

Philip Serlin: I would like to take a few moments to summarize our key upcoming milestones. Potential FDA approval of APHEXDA in September 2023. The potential U.S. launch of APHEXDA stem cell mobilization shortly after approval. Initiation of a clinical trial in collaboration with Washington University School of Medicine to evaluate Motixafortide as monotherapy and in combination with natalizumab for CD34-positive hematopoietic stem cell mobilization for gene therapies in sickle cell disease in 2023. Initiation of Phase IIb randomized clinical trial with 200 patients, assessing Motixafortide in combination with the PD-1 inhibitor and standard-of-care chemotherapy as a first-line metastatic PDAC therapy with collaboration partner GenFleet in 2023.
An initial cohort data from the ongoing Columbia University investigated initiated trial evaluating Motixafortide in combination with the PD-1 inhibitor LIBTAYO and standard-of-care chemotherapy in first-line metastatic PDAC patients also in 2023.

https://finance.yahoo.com/news/biolinerx-ltd-nasdaq-blrx-q4-111552192.html